Oncopeptides AB (ONCO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Swedencare AB

Camurus AB

Oncopeptides AB

Calliditas Therapeutics AB

Egetis Therapeutics AB

Vicore Pharma Holding AB

Hansa Biopharma AB

Xbrane Biopharma AB

Xspray Pharma AB

Infant Bacterial Therapeutics AB

FluoGuide A/S

Why is Oncopeptides AB ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 13.09% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -546.33

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 22.12%, its profits have risen by 12.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Oncopeptides AB for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Oncopeptides AB

25.65%

-0.41

126.17%

OMX Stockholm 30

30.13%

1.89

15.95%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

135.37%

EBIT Growth (5y)

13.09%

EBIT to Interest (avg)

-546.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.91

Sales to Capital Employed (avg)

0.37

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-11.14

EV to EBIT

-3.06

EV to EBITDA

-3.06

EV to Capital Employed

-48.44

EV to Sales

9.84

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company

OPERATING CASH FLOW(Y)

Highest at SEK -200.16 MM

RAW MATERIAL COST(Y)

Fallen by 1.91% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 2.17 times

NET SALES(Q)

Highest at SEK 25.38 MM

OPERATING PROFIT(Q)

Highest at SEK -40.7 MM

OPERATING PROFIT MARGIN(Q)

Highest at -160.35 %

PRE-TAX PROFIT(Q)

Highest at SEK -32.06 MM

NET PROFIT(Q)

Highest at SEK -32.19 MM

EPS(Q)

Highest at SEK -0.12

-11What is not working for the Company

INTEREST(HY)

At SEK 2.46 MM has Grown at 212.31%

ROCE(HY)

Lowest at -623.33%

DEBT-EQUITY RATIO (HY)

Highest at -96.83 %

Here's what is working for Oncopeptides AB

Operating Cash Flow

Highest at SEK -200.16 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Net Sales

Highest at SEK 25.38 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (SEK MM)

Net Sales

At SEK 25.38 MM has Grown at 42.52%

over average net sales of the previous four periods of SEK 17.81 MM

MOJO Watch

Near term sales trend is positive

Net Sales (SEK MM)

Operating Profit

Highest at SEK -40.7 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Operating Profit Margin

Highest at -160.35 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at SEK -32.06 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Pre-Tax Profit

At SEK -32.06 MM has Grown at 48.32%

over average net sales of the previous four periods of SEK -62.04 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit

Highest at SEK -32.19 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

Net Profit

At SEK -32.19 MM has Grown at 48.42%

over average net sales of the previous four periods of SEK -62.4 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

EPS

Highest at SEK -0.12

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (SEK)

Debtors Turnover Ratio

Highest at 2.17 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.91% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Oncopeptides AB

Interest

At SEK 2.46 MM has Grown at 212.31%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Debt-Equity Ratio

Highest at -96.83 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio